Boyce Sarah 4

4 · Contineum Therapeutics, Inc. · Filed Jun 26, 2026

AI-generated summary of this filing

Updated Jun 26, 2026

Contineum (CTNM) Director Sarah Boyce Receives 19,000-Share Option Award

What Happened

Sarah Boyce, a non-employee director of Contineum Therapeutics (CTNM), received an award of options covering 19,000 shares on 2026-06-26. The filing reports the acquisition as a derivative grant (code A) with $0.00 shown for the acquisition price—this reflects an option award, not an immediate cash purchase of shares.

Key Details

Transaction date: 2026-06-26 (filed the same day).
Grant: options for 19,000 shares (reported acquisition price $0.00).
Vesting: options vest in full on the earlier of (i) June 26, 2027 (one year after grant) or (ii) the next regular annual meeting of stockholders, subject to continuous service (per footnote).
Plan: granted under the Issuer’s 2024 Equity Incentive Plan and the Non‑Employee Director Compensation Program (automatic annual grant for continuing non-employee directors).
Shares owned after transaction: not specified in the provided filing excerpt.
Timeliness: filing date equals transaction date; no late filing indicated.

Context

This is a routine director compensation award (option grant). It does not represent immediate share ownership or an open‑market purchase/sale; any future impact depends on vesting, exercise terms (exercise price not shown in the excerpt), and whether shares are later sold. Such awards are common for non-employee directors and are primarily compensation rather than a direct buy/sell signal.

Form 4

Period: 2026-06-26

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-06-26+19,000→ 19,000 total
Exercise: $14.19Exp: 2036-06-25→ Class A Common Stock (19,000 underlying)

Footnotes (1)

[F1]Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-06-26

1 file